Use of hormone therapies in disseminated carcinomatosis of the bone marrow associated with hormone receptor-positive breast cancer

被引：3
作者：
Ota, Takayo [1 ]
Miyatake, Nozomi [1 ]
Tanaka, Noriko [2 ]
Hasegawa, Yoshikazu [1 ]
Tokunaga, Masahiro [2 ]
Tsukuda, Hiroshi [1 ]
Fukuoka, Masahiro [1 ]
机构：
[1] Izumi Municipal Hosp, Dept Med Oncol, 4-10-10 Fuchu, Izumi, Osaka 5940071, Japan
[2] Izumi Municipal Hosp, Dept Radiol, Izumi, Osaka, Japan
来源：
GYNECOLOGICAL ENDOCRINOLOGY | 2018年 / 34卷 / 04期
关键词：
Breast cancer; disseminated carcinomatosis of the bone marrow; hormone therapy; zoledronic acid; GASTRIC-CANCER; METASTASIS; PROGNOSIS;
D O I：
10.1080/09513590.2017.1393063
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Disseminated carcinomatosis of the bone marrow (DCBM) is diffusely invasive bone metastasis resulting from solid tumors. DCBM is often associated with disseminated intravascular coagulation (DIC) or hemolytic anemia. Generally, DCBM treatment includes cytotoxic chemotherapy for underlying solid tumors and management of hematological conditions if present. We report a case of DCBM accompanied with DIC in hormone receptor-positive breast cancer. Due to her life-threatening condition, we used hormone therapies, not cytotoxic chemotherapies, to treat her DCBM. With zoledronic acid, her DIC and general condition gradually improved and eventually she could return to her daily life. If DCBM occurs in hormone receptor-positive breast cancer, hormone therapy can be one of the treatment choices.
引用
收藏
页码：286 / 289
页数：4
相关论文
共 50 条
[41]   Poor prognosis of single hormone receptor-positive breast cancer: similar outcome as triple-negative breast cancer [J].
Bae, Soo Youn ;
Kim, Sangmin ;
Lee, Jun Ho ;
Lee, Hyun-chul ;
Lee, Se Kyung ;
Kil, Won Ho ;
Kim, Seok Won ;
Lee, Jeong Eon ;
Nam, Seok Jin .
BMC CANCER, 2015, 15
[42]   The evolving landscape of metastatic HER2-positive, hormone receptor-positive Breast Cancer [J].
Bielo, Luca Boscolo ;
Trapani, Dario ;
Nicolo, Eleonora ;
Valenza, Carmine ;
Guidi, Lorenzo ;
Belli, Carmen ;
Kotteas, Elias ;
Marra, Antonio ;
Prat, Aleix ;
Fusco, Nicola ;
Criscitiello, Carmen ;
Burstein, Harold J. ;
Curigliano, Giuseppe .
CANCER TREATMENT REVIEWS, 2024, 128
[43]   Estrogen receptor-negative/progesterone receptor-positive and her-2-negative breast cancer might no longer be classified as hormone receptor-positive breast cancer [J].
Zheng, Hongjuan ;
Ge, Chenyang ;
Lin, Haiping ;
Wu, Lunpo ;
Wang, Qinghua ;
Zhou, Shishi ;
Tang, Wanfen ;
Zhang, Xia ;
Jin, Xiayun ;
Xu, Xifeng ;
Hong, Zhongwu ;
Fu, Jianfei ;
Du, Jinlin .
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2022, 27 (07) :1145-1153
[44]   Estrogen receptor-negative/progesterone receptor-positive and her-2-negative breast cancer might no longer be classified as hormone receptor-positive breast cancer [J].
Hongjuan Zheng ;
Chenyang Ge ;
Haiping Lin ;
Lunpo Wu ;
Qinghua Wang ;
Shishi Zhou ;
Wanfen Tang ;
Xia Zhang ;
Xiayun Jin ;
Xifeng Xu ;
Zhongwu Hong ;
Jianfei Fu ;
Jinlin Du .
International Journal of Clinical Oncology, 2022, 27 :1145-1153
[45]   Use of neoadjuvant versus adjuvant chemotherapy for hormone receptor-positive breast cancer: a National Cancer Database (NCDB) study [J].
Michael Zeidman ;
J. Jaime Alberty-Oller ;
Meng Ru ;
Kereeti V. Pisapati ;
Erin Moshier ;
Soojin Ahn ;
Madhu Mazumdar ;
Elisa Port ;
Hank Schmidt .
Breast Cancer Research and Treatment, 2020, 184 :203-212
[46]   Use of neoadjuvant versus adjuvant chemotherapy for hormone receptor-positive breast cancer: a National Cancer Database (NCDB) study [J].
Zeidman, Michael ;
Alberty-Oller, J. Jaime ;
Ru, Meng ;
Pisapati, Kereeti V. ;
Moshier, Erin ;
Ahn, Soojin ;
Mazumdar, Madhu ;
Port, Elisa ;
Schmidt, Hank .
BREAST CANCER RESEARCH AND TREATMENT, 2020, 184 (01) :203-212
[47]   Adenylate cyclase 9 expression level is associated with hormone receptor-positive breast cancer and predicts patient prognosis [J].
Sugino, Kayoko ;
Shibata, Masahiro ;
Adachi, Yayoi ;
Soeda, Ikumi ;
Ichikawa, Takahiro ;
Inaishi, Takahiro ;
Kanaya, Emi ;
Kanda, Mitsuro ;
Hayashi, Masamichi ;
Masuda, Norikazu .
NAGOYA JOURNAL OF MEDICAL SCIENCE, 2024, 86 (04) :665-682
[48]   Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer [J].
Ditsch, Nina ;
Schmidt, Marcus .
GEBURTSHILFE UND FRAUENHEILKUNDE, 2019, 79 (12) :1328-1335
[49]   MicroRNA-222 Expression as a Predictive Marker for Tumor Progression in Hormone Receptor-Positive Breast Cancer [J].
Han, Song-Hee ;
Kim, Hyun Jeong ;
Gwak, Jae Moon ;
Kim, Mimi ;
Chung, Yul Ri ;
Park, So Yeon .
JOURNAL OF BREAST CANCER, 2017, 20 (01) :35-44
[50]   Neoadjuvant therapy in hormone Receptor-Positive/HER2-Negative breast cancer [J].
Cantini, Luca ;
Trapani, Dario ;
Guidi, Lorenzo ;
Bielo, Luca Boscolo ;
Scafetta, Roberta ;
Koziej, Marcin ;
Vidal, Laura ;
Saini, Kamal S. ;
Curigliano, Giuseppe .
CANCER TREATMENT REVIEWS, 2024, 123
12345